Preferred Prescribing list for South Staffordshire CCGs, including Burton Hospital NHS Foundation Trust and
Cannock and Stafford Hospitals Foundation Trust
|
Useful Links
|
| News Feed |
|
10/12/2020: New ESCAs in North Staffordshire
Two ESCAs were approved by the Area Prescribing Committee (North) in September 2020 for use in North Staffordshire. They are:
- Methotrexate for the treatment of Autoimmune Rheumatic diseases (Version 4.1)- This was updated to include additional monitoring information if prescribed concurrently with Leflunomide.
- Tizanidine for the treatment of spasticity associated with brain injuries, multiple sclerosis or spinal cord injury or disease (Version 1.0)- This is a new ESCA developed by MPFT.
Note that both drugs have an ‘Amber-E’ status on the North Staffs formulary for the relevant indications, thus transfer of prescribing into primary care MUST be accompanied by an agreed ESCA form.
All APC approved ESCAs for the North are available on netFormulary via the link: http://www.northstaffordshirejointformulary.nhs.uk/docs/esca/
For any prescribing-related issues, please contact the respective medicines optimisation team.
|
|
3/11/2020 PRODUCT DISCONTINUATION:
Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen (exenatide once-weekly) will be discontinued from 31/12/2020. Clinicians should note that the old device is being replaced by the Bydureon BCise pen (exenatide 2mg prolonged-release injectable suspension); a once weekly, single use, fixed dose pen with a hidden needle that automatically injects the required dose, allowing for simpler administration compared to the old Bydureon device. Prior to prescribing and administration of this new device, patient and caregivers training must be undertaken by a healthcare professional
|
|
7/10/20 Smoking Cessation Information Update
Everyone Health, the service provider for smoking cessation service confirms it is now open to all tobacco smokers, living anywhere in Staffordshire, aged 40 years and over. Referrals can still be made by calling the contact centre on 0333 005 0095, or via email: eh.staffs@nhs.net
|
|
4/8/20 Updated Gluten-Free Prescribing policy 2020
The updated Gluten-Free Prescribing policy 2020 can be found on the Homepage, Area Prescribing Group Guidelines link, BNF Chapter 9 Nutrition and Blood – Gluten Free prescribing on the South Staffordshire Joint Formulary.
|
|
24/7/2020 - Updated Rheumatology ESCA’s
Midlands Partnership NHS Foundation Trust (MPFT) have updated their contact details for their Rheumatology ESCA’s to reflect their dedicated email address:haywoodrheumatology@esca.nhs.net
The updated documents can be found on the ESCA’s link on the North Staffordshire Joint Formulary Home page.
|
|
07/05/2020 - New Covid-19 information link
The South Staffordshire Joint Formulary has a new COVID 19 link titled Interim Clinical Information. Please use this link to access local and national documents recommending advice and guidance during this time. If you have any queries relating to this please use the Feedback tab on the formulary front page.
Medicines Information Team
|
| >>> more news |
|
HOW TO USE
- The Preferred Prescribing List for the various therapeutic sections of the British National Formulary (BNF) can be accessed via the links
2.  How to use guide
3. Drugs are colour coded according to the following criteria:
| Status |
Description |
  |
Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care. |
 |
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care. |
 |
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement) |
 |
Suitable first-line drugs for implementation in Primary Care |
 |
South Staffs Formulary Choice |
|
|
